Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial

Core Insights - Pyxis Oncology, Inc. is making significant progress in its clinical program for PYX-201, an antibody-drug conjugate (ADC) targeting Extradomain-B Fibronectin (EDB+FN), which is highly expressed in various tumor types [1][10] - The company is actively recruiting for two trials: one evaluating PYX-201 as a monotherapy for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) and another combining PYX-201 with Merck's KEYTRUDA® in patients with advanced solid tumors [2][3] Clinical Trials - The Phase 1/2 combination study, PYX-201-102, is set to initiate patient dosing in Q1 2025, focusing on the combination of PYX-201 with pembrolizumab across multiple indications [3][6] - The ongoing Phase 1 PYX-201-101 study has begun enrolling patients for its monotherapy expansion cohorts, targeting advanced solid tumors predicted to express EDB+FN [5][9] Treatment Potential - PYX-201 is designed to deliver its AUR-0101 payload specifically within the tumor microenvironment, potentially enhancing the efficacy of pembrolizumab by allowing T cells to infiltrate challenging tumor microenvironments [3][10] - The ongoing trials represent a critical step in advancing PYX-201 as a potential breakthrough treatment for a broad range of cancers, particularly for patients with limited treatment options [3][11]